These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 29633166)

  • 1. A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.
    Durgam S; Chen C; Migliore R; Prakash C; Edwards J; Findling RL
    Paediatr Drugs; 2018 Aug; 20(4):353-363. PubMed ID: 29633166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.
    Findling RL; McCusker E; Strawn JR
    J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):355-365. PubMed ID: 32460523
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Mathews M; Gommoll C; Chen D; Nunez R; Khan A
    Int Clin Psychopharmacol; 2015 Mar; 30(2):67-74. PubMed ID: 25500685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
    J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
    J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial.
    Durgam S; Gommoll C; Migliore R; Chen C; Chang CT; Aguirre M; Thase ME
    Int Clin Psychopharmacol; 2018 Nov; 33(6):304-311. PubMed ID: 30044247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials.
    Thase ME; Edwards J; Durgam S; Chen C; Chang CT; Mathews M; Gommoll CP
    Int Clin Psychopharmacol; 2017 Sep; 32(5):281-288. PubMed ID: 28538024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.
    Gommoll C; Durgam S; Mathews M; Forero G; Nunez R; Tang X; Thase ME
    Depress Anxiety; 2015 Jun; 32(6):451-9. PubMed ID: 25891440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.
    DelBello MP; Hochadel TJ; Portland KB; Azzaro AJ; Katic A; Khan A; Emslie G
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):311-7. PubMed ID: 24955812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
    Emslie GJ; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):170-9. PubMed ID: 24815533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Atkinson SD; Prakash A; Zhang Q; Pangallo BA; Bangs ME; Emslie GJ; March JS
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):180-9. PubMed ID: 24813026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials.
    Jain R; Chen D; Edwards J; Mathews M
    Curr Med Res Opin; 2014 Feb; 30(2):263-70. PubMed ID: 24127687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.
    Wagner KD; Ambrosini P; Rynn M; Wohlberg C; Yang R; Greenbaum MS; Childress A; Donnelly C; Deas D;
    JAMA; 2003 Aug; 290(8):1033-41. PubMed ID: 12941675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vilazodone: a review in major depressive disorder in adults.
    McCormack PL
    Drugs; 2015 Nov; 75(16):1915-23. PubMed ID: 26496736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
    Radecki DT; Robieson WZ; Gopalkrishnan M; Greenberg E; Aziz M
    J Child Adolesc Psychopharmacol; 2024 Jun; 34(5):241-250. PubMed ID: 38700708
    [No Abstract]   [Full Text] [Related]  

  • 19. Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial.
    Findling RL; Robb A; Bose A
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):468-80. PubMed ID: 24041408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder.
    Rele S; Millet R; Kim S; Paik JW; Kim S; Masand PS; Patkar AA
    Prim Care Companion CNS Disord; 2015; 17(4):. PubMed ID: 26693034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.